The DOI matches its Crossref record; 112 of the 112 references it cites were found in a registry or an index.
Antibiotics in the clinical pipeline in 2011
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Bad Bugs, No Drugs: No ESKAPE! An Update from the Infectious Diseases Society of America
Boucher, H. W., Talbot, G. H., Bradley, J. S., Edwards, J. E., Gilbert, D., Rice, L. B., Scheld, M., Spellberg, B., & Bartlett, J. (2009) · Clinical Infectious Diseases · doi:10.1086/595011 · Cited by 4,958
Ranade, V. V. (2009) · American Journal of Therapeutics · doi:10.1097/mjt.0b013e31817c941f · Cited by 2,775
Drugs for bad bugs: confronting the challenges of antibacterial discovery
Payne, D. J., Gwynn, M. N., Holmes, D. J., & Pompliano, D. L. (2007) · Nature Reviews Drug Discovery · doi:10.1038/nrd2201 · Cited by 2,512
Federal Funding for the Study of Antimicrobial Resistance in Nosocomial Pathogens: No ESKAPE
Rice, L. B. (2008) · The Journal of Infectious Diseases · doi:10.1086/533452 · Cited by 2,310
A Diarylquinoline Drug Active on the ATP Synthase of Mycobacterium tuberculosis
Andries, K., Verhasselt, P., Guillemont, J., Göhlmann, H. W. H., Neefs, J.-M., Winkler, H., Van Gestel, J., Timmerman, P., Zhu, M., Lee, E., et al. (2005) · Science · doi:10.1126/science.1106753 · Cited by 2,191
Challenges of Antibacterial Discovery
Silver, L. L. (2011) · Clinical Microbiology Reviews · doi:10.1128/cmr.00030-10 · Cited by 1,376
The challenge of new drug discovery for tuberculosis
Koul, A., Arnoult, E., Lounis, N., Guillemont, J., & Andries, K. (2011) · Nature · doi:10.1038/nature09657 · Cited by 1,042
The Diarylquinoline TMC207 for Multidrug-Resistant Tuberculosis
Diacon, A. H., Pym, A., Grobusch, M., Patientia, R., Rustomjee, R., Page-Shipp, L., Pistorius, C., Krause, R., Bogoshi, M., Churchyard, G., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0808427 · Cited by 835
Matsumoto, M., Hashizume, H., Tomishige, T., Kawasaki, M., Tsubouchi, H., Sasaki, H., Shimokawa, Y., & Komatsu, M. (2006) · PLoS Medicine · doi:10.1371/journal.pmed.0030466 · Cited by 751
Lipid II as a target for antibiotics
Breukink, E., & de Kruijff, B. (2006) · Nature Reviews Drug Discovery · doi:10.1038/nrd2004 · Cited by 701
Cited by
Designing antimicrobial peptides: form follows function
Fjell, C. D., Hiss, J. A., Hancock, R. E. W., & Schneider, G. (2012) · Nature Reviews Drug Discovery · doi:10.1038/nrd3591 · Cited by 2,035
Clinical relevance of the ESKAPE pathogens
Pendleton, J. N., Gorman, S. P., & Gilmore, B. F. (2013) · Expert Review of Anti-infective Therapy · doi:10.1586/eri.13.12 · Cited by 1,423
Ribosome-targeting antibiotics and mechanisms of bacterial resistance
Wilson, D. N. (2014) · Nature Reviews Microbiology · doi:10.1038/nrmicro3155 · Cited by 1,054
Antibiotics in the clinical pipeline in 2013
Butler, M. S., Blaskovich, M. A., & Cooper, M. A. (2013) · The Journal of Antibiotics · doi:10.1038/ja.2013.86 · Cited by 433
Self-citationFormation, physiology, ecology, evolution and clinical importance of bacterial persisters
Van den Bergh, B., Fauvart, M., & Michiels, J. (2017) · FEMS Microbiology Reviews · doi:10.1093/femsre/fux001 · Cited by 381
Prospects for new antibiotics: a molecule-centered perspective
Walsh, C. T., & Wencewicz, T. A. (2014) · The Journal of Antibiotics · doi:10.1038/ja.2013.49 · Cited by 372
Nanocarriers for antibiotics: A promising solution to treat intracellular bacterial infections
Abed, N., & Couvreur, P. (2014) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2014.02.009 · Cited by 358
Antibiotics in the clinical pipeline at the end of 2015
Butler, M. S., Blaskovich, M. A., & Cooper, M. A. (2017) · The Journal of Antibiotics · doi:10.1038/ja.2016.72 · Cited by 349
Self-citationPharmacokinetic-Pharmacodynamic Modeling of Antibacterial Drugs
Nielsen, E. I., & Friberg, L. E. (2013) · Pharmacological Reviews · doi:10.1124/pr.111.005769 · Cited by 332
Glycopeptide antibiotics: Back to the future
Butler, M. S., Hansford, K. A., Blaskovich, M. A. T., Halai, R., & Cooper, M. A. (2014) · The Journal of Antibiotics · doi:10.1038/ja.2014.111 · Cited by 303
Self-citationAntibiotic Hybrids: the Next Generation of Agents and Adjuvants against Gram-Negative Pathogens?
Domalaon, R., Idowu, T., Zhanel, G. G., & Schweizer, F. (2018) · Clinical Microbiology Reviews · doi:10.1128/cmr.00077-17 · Cited by 285
Antibiotics in the clinical pipeline in October 2019
Butler, M. S., & Paterson, D. L. (2020) · The Journal of Antibiotics · doi:10.1038/s41429-020-0291-8 · Cited by 264
Self-citationIndustrial natural product chemistry for drug discovery and development
Bauer, A., & Brönstrup, M. (2014) · Nat. Prod. Rep. · doi:10.1039/c3np70058e · Cited by 255
Target- and resistance-based mechanistic studies with TP-434, a novel fluorocycline antibiotic
Grossman, T. H., Starosta, A. L., Fyfe, C., O'Brien, W., Rothstein, D. M., Mikolajka, A., Wilson, D. N., & Sutcliffe, J. A. (2012) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.06187-11 · Cited by 162
De Cremer, K., Lanckacker, E., Cools, T. L., Bax, M., De Brucker, K., Cos, P., Cammue, B. P. A., & Thevissen, K. (2015) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.04229-14 · Cited by 77
Protein‐protein interactions as antibiotic targets: A medicinal chemistry perspective
Cossar, P. J., Lewis, P. J., & McCluskey, A. (2020) · Medicinal Research Reviews · doi:10.1002/med.21519 · Cited by 55
Metadata
- Authors
- Butler, M. S., & Cooper, M. A.
- Venue
- The Journal of Antibiotics
- Published
- 2011-05-18
- Volume
- 64
- Issue
- 6
- Pages
- 413-425
- ISSN
- 0021-8820 (ISSN-L)
- 1881-1469
- OpenAlex
- W2083190721
- Cited by
- 272
- References
- 112
- FWCI
- 16.96
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.